67 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
:
Accounts payable
Other accrued liabilities
Lease liability, current
Total current liabilities
Lease liability, net of current portion
Total long-term liabilities
8-K
EX-1.1
VKTX
Viking Therapeutics Inc
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
stock or long‑term debt of the Company or any of its subsidiaries, taken as a whole (other than changes pursuant to agreements or employee benefit
8-K
EX-99.1
cx1lal 12g8jbdf7t2vz
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
bjfmu7 az1guu
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
8-K
EX-99.1
q3b wiw61n333
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
j7k4ad
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
w8jxah8n9148
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-1.1
n57j2qt mxuuxx
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
8-K
EX-99.1
9smqnka5nb1vejf5st2d
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
7suqp4c3iaie1j
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm